Market Newsdesk

SINGAPORE, May 25, 2026 /PRNewswire/ — VinFast Auto Ltd. (“VinFast” or the “Company”) announced that its Board of Directors has appointed Mr. Pham Nhat Quan Anh as Chairman of the Board of the Company. The appointment is intended to support the Company’s global expansion requirements in its next phase of development.

The Board of Directors of VinFast has approved the appointment of Mr. Pham Nhat Quan Anh as Chairman of the Board of Directors, effective May 23, 2026, replacing Ms. Le Thi Thu Thuy. This transition is expected to establish a strong foundation for sustainable growth in the future.

Mr. Pham Nhat Quan Anh currently serves as Vice Chairman and Standing Deputy General Director at VinFast Trading and Production JSC. With extensive multi-industry management experience, he has made significant contributions to VinFast’s development journey, from its initial foundation-building phase in the domestic market to the Company’s global expansion strategy.

Ms. Le Thi Thu Thuy will cease to serve as Chairwoman and member of the Board of Directors of the Company. She will continue to serve as Vice Chairwoman of Vingroup, VinFast’s major shareholder, where she will focus on key strategic priorities.

Mr. Pham Nhat Quan Anh commented: “I am honored to assume the role of Chairman of the Board of VinFast. VinFast has built a strong foundation over the past several years, and we remain focused on executing the Company’s long-term strategic priorities, advancing innovation, and continuing to strengthen our global operations and customer experience. I look forward to working closely with the leadership team as VinFast enters its next stage of growth.”

Mr. Anh holds a Bachelor’s degree in business management from Singapore Management University. Prior to joining VinFast, Mr. Anh served as Deputy General Director and Deputy Chief Operating Officer of Vinpearl Joint Stock Company from 2017 to 2019, where he gained extensive experience in operational management and strategic planning across the hospitality and services industries.

Since joining VinFast in February 2019, he has held several senior leadership positions across vehicle development, manufacturing, sales and after-sales services, including Deputy General Director of Global Sales, Marketing and Aftersales, and Director of the Planning, Program Coordination and Quality Inspection Division, prior to his current positions. In these roles, he has been instrumental in supporting VinFast’s rapid development and expansion from its initial localization phase in Vietnam to its global strategy.

View original content to download multimedia:https://www.prnewswire.com/news-releases/vinfast-names-mr-pham-nhat-quan-anh-as-chairman-of-the-board-of-directors-302781237.html

SOURCE VinFast

NEW YORK, May 25, 2026 /PRNewswire/ —

Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of LKQ Corporation (NASDAQ: LKQ) between February 27, 2023 and July 23, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 22, 2026.

So What: If you purchased LKQ common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do Next: To join the LKQ class action, go to https://rosenlegal.com/submit-form/?case_id=62121 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 22, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the Case: According to the lawsuit, throughout the Class Period, LKQ repeatedly touted the benefits of the acquisition of FinishMaster, a subsidiary of Uni-Select. For example, in announcing the acquisition in February 2023, LKQ represented that the acquisition was a “compelling strategic fit” to “enhance LKQ’s business and drive profitable growth.” LKQ also represented that the acquisition presented “minimal integration risk,” including because “Uni-Select’s FinishMaster business improves LKQ’s scale and product mix to compete” in the North American automotive paint segment.

After completing the acquisition in August 2023, LKQ began to integrate FinishMaster into LKQ’s North American operating segment. LKQ and its executives touted the integration as a “highly synergistic opportunity” and “competitive moat” to protect LKQ against market share losses to AutoZone and other competitors. In reality, FinishMaster was losing major customers and market share, including the business of key multi-shop operator clients that were critical to FinishMaster’s revenue. When the true details entered the market, the lawsuit claims that investors suffered damages. 

To join the LKQ class action, go to https://rosenlegal.com/submit-form/?case_id=62121 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40^th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/lkq-investors-have-opportunity-to-lead-lkq-corporation-securities-fraud-lawsuit-302780393.html

SOURCE THE ROSEN LAW FIRM, P. A.

CALGARY, AB, May 25, 2026 /PRNewswire/ – Enbridge Inc. (TSX: ENB) (NYSE: ENB) (Enbridge) and its wholly owned subsidiary Enbridge Pipelines Inc. (EPI) today announced that they are seeking the approval of the holders (EPI Noteholders) of all outstanding series of EPI’s medium term note debentures listed below (EPI Notes) to exchange all outstanding EPI Notes for an equal principal amount of newly issued medium term notes of Enbridge (Enbridge Notes), having financial terms that are the same as the financial terms of the EPI Notes (the Note Exchange Transaction). The Enbridge Notes will be governed by Enbridge’s existing medium term note trust indenture dated as of October 20, 1997, as amended and supplemented, which governs Enbridge’s other senior Canadian dollar unsecured debt securities.

The Note Exchange Transaction is being proposed to give EPI flexibility to operate its business , while also delivering a range of operational, structural and capital markets benefits to EPI, Enbridge and the EPI Noteholders. Please see EPI’s management information circular and consent solicitation statement dated May 25, 2026 (the Circular) for additional information regarding the Note Exchange Transaction, including the rationale for the Note Exchange Transaction.

EPI is soliciting consents and proxies from EPI Noteholders, as a single class, to pass an extraordinary resolution to approve the Note Exchange Transaction (the Note Exchange Resolution).

The deadline for the submission of written consents is 5:00 p.m. (Toronto time) on June 10, 2026, unless extended by EPI in its sole discretion (the Consent Deadline).

The deadline for deposit of proxies for the Meeting (as defined below), if held, is 12:00 p.m. (Toronto time) on June 23, 2026, unless the Meeting is adjourned or postponed (the Proxy Deadline).

If EPI Noteholders holding not less than 75% of the aggregate principal amount of the EPI Notes deliver valid written consents in favor of the Note Exchange Resolution by the Consent Deadline, the Note Exchange Resolution will be passed by written consent and the meeting of EPI Noteholders scheduled for 10:00 a.m. (Calgary time) / 12:00 p.m. (Toronto time) on June 25, 2026, to be held in Calgary, Alberta, to approve the Note Exchange Resolution (the Meeting) will be cancelled.

The following EPI Notes will be eligible to participate in the Note Exchange Transaction:

The record date for determining the EPI Noteholders entitled to vote on the Note Exchange Transaction has been set as the close of business (Toronto time) on May 20, 2026.

If the Note Exchange Resolution is approved via written consent or at the Meeting, EPI Noteholders that have validly provided their written consent and proxy by the applicable deadline will receive the applicable amendment review fees (Amendment Review Fees) as noted in the table above and described in the Circular. No amendment review fee will be payable to EPI Noteholders unless the Note Exchange Resolution is approved.

EPI reserves the right to extend or modify the Consent Deadline at any time in its sole discretion. In the event that the Consent Deadline is extended and the required 75% approval threshold for the Note Exchange Resolution is achieved prior to the Proxy Deadline, EPI will cancel the Meeting. In such circumstances, EPI Noteholders may have minimal notice that the Meeting has been cancelled. Accordingly, EPI Noteholders should submit elections with respect to the Note Exchange Resolution as soon as possible, and prior to the Consent Deadline of 5:00 p.m. (Toronto time) on June 10, 2026, to be assured of their entitlement to Amendment Review Fees.

BMO Nesbitt Burns Inc. (BMO Capital Markets) is the Solicitation Agent for the Note Exchange Transaction, Computershare Investor Services Inc. is retained as the Tabulation Agent and Sodali & Co. is retained as the Information Agent.

Copies of the Circular and any other proxy and consent solicitation materials may be obtained free of charge upon request made to the Information Agent by calling toll free in North America at 1-833-830-9927 (1-289-695-3075 by collect call) or by email at [email protected]. They may also be accessed electronically on EPI’s profile on SEDAR+ at www.sedarplus.com and by written request to 200, 425 – 1st Street S.W., Calgary, Alberta, T2P 3L8, Attn: Investor Relations, or by sending an email to [email protected].

Questions concerning the Meeting and the Note Exchange Transaction should be directed to BMO Capital Markets by telephone at 1-416-359-6359 or toll-free at 1-833-418-0762 or by email at [email protected].

NOTICE TO EPI NOTEHOLDERS IN THE UNITED STATES
The Enbridge Notes to be issued in connection with the Note Exchange Transaction have not been registered under the U.S. Securities Act of 1933, as amended (the U.S. Securities Act) and are being issued pursuant to an exemption from the registration requirements of the U.S. Securities Act provided by Rule 802 thereunder.

The Note Exchange Transaction described in this press release is made for the securities of a Canadian corporation. The Note Exchange Transaction is subject to the disclosure requirements of Canada, and EPI Noteholders in the United States (U.S. EPI Noteholders) should be aware that the foregoing disclosure requirements are different from those of the United States.

It may be difficult for U.S. EPI Noteholders to enforce their rights and any claims U.S. EPI Noteholders may have arising under U.S. federal securities laws, since EPI and Enbridge are located in Canada, and many of their officers and directors are residents of Canada. U.S. EPI Noteholders may not be able to sue a Canadian corporation or its officers or directors in a Canadian court for violations of U.S. securities laws. It may be difficult to compel a Canadian corporation and its affiliates to subject themselves to a U.S. court’s judgment.

U.S. EPI Noteholders should be aware that, prior to the consummation of the Note Exchange Transaction, EPI, Enbridge or their respective affiliates, directly or indirectly, may bid for or make purchases of EPI Notes or certain related securities, as permitted by applicable laws and regulations of the United States or Canada or its provinces or territories.

FORWARD-LOOKING STATEMENTS

Forward-looking information, or forward-looking statements, has been included in this news release to provide information about Enbridge and EPI, including statements with respect to: the date and timing of the Meeting, the approval by EPI Noteholders of the Note Exchange Resolution, the completion of the Note Exchange Transaction, the terms of the Enbridge Notes to be issued to EPI Noteholders in exchange for their EPI Notes, the amendment review fees to be paid to EPI Noteholders if the Note Exchange Resolution is approved and the Note Exchange Transaction is completed, and the pursuit or implementation of any transactions or other activities by EPI. This information may not be appropriate for other purposes. Although Enbridge and EPI believe that these forward-looking statements are reasonable based on the information available on the date such statements are made and processes used to prepare the information, such statements are not guarantees of future performance and readers are cautioned against placing undue reliance on forward-looking statements. By their nature, these statements involve a variety of assumptions, known and unknown risks and uncertainties and other factors, which may cause actual result, levels of activity and achievements to differ materially from those expressed or implied by such statements. Material assumptions include assumptions about the approval of the Note Exchange Resolution, the completion of the Note Exchange Transaction and the business and financial strength of Enbridge and EPI.

The forward-looking statements contained herein are subject to risks and uncertainties pertaining to the approval of the Note Exchange Resolution and the completion of the Note Exchange Transaction. The impact of any one risk, uncertainty or factor on a particular forward-looking statement is not determinable with certainty as these are interdependent and Enbridge’s and EPI’s future course of action depends on management’s assessment of all information available at the relevant time. Except to the extent required by applicable law, Enbridge and EPI assume no obligation to publicly update or revise any forward-looking statements made in this news release or otherwise, whether as a result of new information, future events or otherwise. All subsequent forward-looking statements, whether written or oral, attributable to Enbridge, EPI or persons acting on their behalf, are expressly qualified in their entirety by these cautionary statements.

About Enbridge Inc.

At Enbridge, we safely connect millions of people to the energy they rely on every day, fueling quality of life through our North American natural gas, oil and renewable power networks and our growing European offshore wind portfolio. We’re investing in modern energy delivery infrastructure to sustain access to secure, affordable energy and building on more than a century of operating conventional energy infrastructure and two decades of experience in renewable power. We’re advancing new technologies including hydrogen, renewable natural gas, and carbon capture and storage. Headquartered in Calgary, Alberta, Enbridge’s common shares trade under the symbol ENB on the Toronto (TSX) and New York (NYSE) stock exchanges. To learn more, visit us at enbridge.com.

None of the information contained in, or connected to, Enbridge’s website is incorporated in or otherwise forms part of this news release.

About Enbridge Pipelines Inc.

EPI is primarily a transporter of western Canadian and United States crude oil, refined petroleum products and natural gas liquids. Its Canadian Mainline System transports crude oil from western Canada to the Midwest region of the United States and eastern Canada and serves all of the major refining centers in Ontario. EPI also operates the Southern Lights Canada Pipeline, which transports diluent from the Canada/United States border to western Canada, and holds investments in renewable and alternative power generation assets.

View original content:https://www.prnewswire.com/news-releases/enbridge-inc-and-enbridge-pipelines-inc-announce-debt-exchange-proposal-302781142.html

SOURCE Enbridge Inc.

In the Phase 1b Heart-2 trial, a single intravenous infusion of VERVE-102 produced dose-dependent lowering of PCSK9 and LDL-C, with both reductions sustained over follow-up of up to 18 months in participants at high risk for cardiovascular disease

VERVE-102 is designed to mimic the protective effect of naturally occurring loss-of-function variants in PCSK9, which are associated with markedly lower lifetime risk of coronary heart disease

Lilly plans to begin enrolling the Phase 2 clinical study of VERVE-102 by the end of this year

INDIANAPOLIS, May 25, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced positive Phase 1b Heart-2 study results for VERVE-102, an investigational in vivo base editing medicine designed to durably turn off the PCSK9 gene in the liver and lower blood low-density lipoprotein cholesterol (LDL-C) following a single infusion. The Heart-2 trial is evaluating VERVE-102 in adults with heterozygous familial hypercholesterolemia (HeFH) or premature coronary artery disease (CAD). These data were presented as a late-breaking oral presentation at the European Atherosclerosis Society (EAS) Congress and simultaneously published in The New England Journal of Medicine.

In the Heart-2 study, a single intravenous infusion of VERVE-102 resulted in meaningful lowering of circulating PCSK9 protein and corresponding reductions in LDL-C across all evaluated dose levels. In this interim analysis of 35 participants, a single dose of VERVE‑102 resulted in dose-dependent mean reductions in PCSK9 ranging from 51% to 88%, at the lowest 0.3 mg/kg dose to the highest 1.0 mg/kg dose, respectively. Corresponding mean reductions in LDL-C were 9% (0.3 mg/kg), 44% (0.45 mg/kg), 45% (0.6 mg/kg), 33% (0.7 mg/kg), 51% (0.8 mg/kg), and 62% (1.0 mg/kg). These reductions were sustained over time, with durability observed for up to 18 months following treatment.

“These early data give us encouraging evidence that in vivo base editing of PCSK9 may offer a novel approach to achieving substantial and durable LDL-C reduction with a one-time treatment,” said Riyaz S. Patel, M.D., cardiologist at Barts Health NHS Trust and professor of cardiology at University College London. “Many patients with elevated LDL-C struggle to achieve sustained control despite ongoing efforts with the medicines available today, putting them at significant risk for cardiovascular events. With coronary artery disease still one of the leading causes of death worldwide, the need for new approaches is real.”

VERVE‑102 was well tolerated across all dose levels with no treatment‑related serious adverse events (AEs) and no dose‑limiting toxicities reported. AEs related to VERVE-102 included low-grade infusion-related reactions and fatigue. All participants received the full planned dose, and no participant withdrew from the study.

“Twenty years ago, genetics showed us that people born with PCSK9 naturally turned off have low LDL-C for life and are remarkably protected from heart attack, yet today’s chronic therapies struggle to deliver this lifelong lowering,” said Sekar Kathiresan, M.D., Lilly senior vice president, and co-founder of Verve Therapeutics. “The Heart-2 results provide early clinical evidence that a single dose of VERVE-102 may mimic the LDL-C lowering effects of PCSK9 cardioprotective variants, potentially transforming cardiovascular care from chronic management to a one-time treatment.”

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VERVE-102 to reduce LDL-C in participants with hyperlipidemia and high lifetime cardiovascular risk. HeFH affects approximately 1 in 200 to 250 people and is characterized by lifelong elevations in LDL-C, leading to premature cardiovascular disease, including CAD.^1,2 Worldwide, CAD remains a leading cause of death, affecting more than 300 million people.³

Lilly plans to initiate the Phase 2 clinical study of VERVE-102 by the end of this year.

About VERVE-102 and VERVE trial programs
VERVE-102, an investigational in vivo base editing medicine, is designed to be a single-course treatment that turns off the PCSK9 gene in the liver and durably reduces disease-driving LDL-C. VERVE-102 consists of a messenger RNA encoding an adenine base editor and a guide RNA (gRNA) targeting the PCSK9 gene. Both are encapsulated in a lipid nanoparticle (LNP) and administered as a single intravenous infusion over approximately four hours. VERVE-102 uses Verve’s proprietary GalNAc-LNP delivery technology, which is designed to allow the LNP to access liver cells using either the low-density lipoprotein receptor (LDLR) or the asialoglycoprotein receptor (ASGPR).

In addition to the PCSK9 program, the Pulse-1 Phase 1b trial for VERVE-201, an investigational in vivo gene editing medicine targeting the ANGPTL3 gene, is ongoing.

About Heart-2

Heart‑2 is an ongoing open‑label, single‑ascending dose Phase 1b study designed to evaluate the safety, tolerability and pharmacodynamic effects of VERVE-102 in adults with HeFH or premature CAD who require additional lowering of LDL-C, despite maximally tolerated oral lipid lowering therapy. This interim analysis included 35 participants who received a single intravenous infusion of VERVE-102 across six dose cohorts (0.3 mg/kg, 0.45 mg/kg, 0.6 mg/kg, 0.7 mg/kg, 0.8 mg/kg and 1.0 mg/kg). All participants received the full planned dose and were followed for at least 28 days, with a subset now followed for up to 18 months. HeFH is diagnosed based on high LDL-C levels, a personal or family history of atherosclerotic cardiovascular disease, physical exam features and/or mutations identified in certain genes. Premature CAD is defined as evidence of CAD (heart attack, coronary revascularization procedure, or coronary atherosclerosis on imaging) occurring in men 55 years old or younger or women 65 years old or younger. Participants are expected to enroll in a long-term follow-up study for up to 15 years. As of the February 27, 2026, data cut-off, the median follow-up duration was approximately nine months, with 15 participants followed for at least one year.

References
1. World Heart Federation. Familial Hypercholesterolemia. Available at: https://world-heart-federation.org/what-we-do/cholesterol/familial-hypercholesterolemia/. Accessed: May 2026.
2. Davletov, K., et al. Prevalence of Familial Hypercholesterolemia and Its Association with Cardiovascular Risk in a Cross-Sectional Adult Population. J Clin Med. 2025 Nov 19;14(22):8213. doi: 10.3390/jcm14228213.
3. Stark, B., et al. Global Prevalence of Coronary Artery Disease: An Update from the Global Burden of Disease Study. ACC. 2024 Apr, 83 (13_Supplement) 2320.

About Lilly

Lilly is a medicine company turning science into healing to make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer’s disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company’s or their rights thereto. We do not intend the use or display of other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about VERVE-102 as a potential treatment for people with heterozygous familial hypercholesterolemia (HeFH) or premature coronary artery disease (CAD) and the timeline for future readouts, presentations, and other milestones relating to VERVE-102 and its clinical trials, and reflects Lilly’s current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, that VERVE-102 will prove to be a safe and effective treatment for people with HeFH or premature CAD, that VERVE-102 will receive regulatory approval, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly’s expectations, see Lilly’s Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/a-single-dose-of-lillys-pcsk9-base-editor-verve-102-reduced-pcsk9-by-up-to-88-and-ldl-c-by-up-to-62-with-durable-effects-supporting-its-potential-as-a-one-time-treatment-for-hypercholesterolemia-302780172.html

SOURCE Eli Lilly and Company